KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) Research & Development (2016 - 2025)

Johnson & Johnson's Research & Development history spans 17 years, with the latest figure at -$10.3 billion for Q4 2025.

  • For Q4 2025, Research & Development fell 2.09% year-over-year to -$10.3 billion; the TTM value through Dec 2025 reached $109.0 million, down 94.08%, while the annual FY2025 figure was $109.0 million, 94.08% down from the prior year.
  • Research & Development for Q4 2025 was -$10.3 billion at Johnson & Johnson, down from $3.7 billion in the prior quarter.
  • Across five years, Research & Development topped out at $5.0 billion in Q3 2024 and bottomed at -$10.3 billion in Q4 2025.
  • The 5-year median for Research & Development is $3.5 billion (2022), against an average of $1.3 billion.
  • The largest annual shift saw Research & Development grew 25.38% in 2021 before it crashed 344.43% in 2023.
  • A 5-year view of Research & Development shows it stood at $3.4 billion in 2021, then increased by 1.84% to $3.5 billion in 2022, then plummeted by 390.44% to -$10.1 billion in 2023, then grew by 0.29% to -$10.1 billion in 2024, then fell by 2.09% to -$10.3 billion in 2025.
  • Per Business Quant, the three most recent readings for JNJ's Research & Development are -$10.3 billion (Q4 2025), $3.7 billion (Q3 2025), and $3.5 billion (Q2 2025).